Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3598)	8/16/1999 7:36:00 AM
From: Herc	Read Replies (3) \| Respond to of 10280

Seldane is an excellent example of what I'm trying to get across. There are literally hundreds of decongestents on the market, and many are OTC. Most people are not overly troubled by the sedative effect of antihistamines so will opt for lower price. My personal favorite is Entex-LA which is just a sympathomimetic without antihistamines. So I wouldn't bet the farm on a new decongestent. OK, if it's successful, than SEPR may be worth twice Merck.

To: BMcV who wrote (3598)	8/16/1999 9:17:00 AM
From: LLCF	Read Replies (1) \| Respond to of 10280

< Have you ever heard of the FDA mandating a switch from the "name" brand to the the "generic", as they have done in the case of Seldane/Allegra? > LOL... if Herc really is a doctor he's probably single handedly resoponsible for the current state of skyrocketing malpractice insurance premiums! I can just see it... "you know, I have a problem with the business model of the company that makes this... here's a prescription for the original version of the same drug, I think it's fine". <g?> DAK